Press Releases

SAN DIEGO --(BUSINESS WIRE)--Apr. 9, 2024-- Tandem Diabetes Care, Inc. (NASDAQ: TNDM), a leading insulin delivery and diabetes technology company, plans to release its first quarter 2024 results after the financial markets close on Thursday, May 2, 2024 .

SAN DIEGO --(BUSINESS WIRE)--Mar. 6, 2024-- Tandem Diabetes Care, Inc. (NASDAQ: TNDM), a global insulin delivery and diabetes technology company, announced today the pricing of $275.0 million aggregate principal amount of 1.50% Convertible Senior Notes due 2029 (the “notes”) in a private placement

SAN DIEGO --(BUSINESS WIRE)--Mar. 4, 2024-- Tandem Diabetes Care, Inc. (NASDAQ: TNDM), a global insulin delivery and diabetes technology company, announced today that it intends to offer, subject to market conditions and other factors, $250.0 million aggregate principal amount of its Convertible

SAN DIEGO --(BUSINESS WIRE)--Feb. 21, 2024-- Tandem Diabetes Care, Inc. (NASDAQ: TNDM), a global insulin delivery and diabetes technology company, today reported its financial results for the quarter and year ended December 31, 2023 and provided its financial guidance for the year ending December

SAN DIEGO --(BUSINESS WIRE)--Feb. 13, 2024-- Tandem Diabetes Care, Inc . (NASDAQ: TNDM), a leading insulin delivery and diabetes technology company, today announced the United States commercial launch of its new Tandem Mobi, the world’s smallest, durable automated insulin delivery system for people

SAN DIEGO --(BUSINESS WIRE)--Feb. 8, 2024-- Tandem Diabetes Care, Inc. (NASDAQ: TNDM), a leading insulin delivery and diabetes technology company, today announced that management will present a company update at the following investor conferences: Citi’s 2024 Unplugged Medtech and Life Sciences

SAN DIEGO --(BUSINESS WIRE)--Jan. 22, 2024-- Tandem Diabetes Care, Inc. (NASDAQ: TNDM), a leading insulin delivery and diabetes technology company, plans to release its fourth quarter and full year 2023 results after the financial markets close on Wednesday, February 21, 2024 .

Abbott’s latest innovation, the FreeStyle Libre ® 2 Plus sensor, is available for the first time for t:slim X2 ™ insulin pump users in the U.S. Tandem’s Control-IQ ™ hybrid closed-loop technology now integrates with the first and only 15-day continuous glucose monitoring (CGM) sensor in the U.S.

SAN DIEGO --(BUSINESS WIRE)--Dec. 12, 2023-- Tandem Diabetes Care, Inc. (NASDAQ: TNDM), a leading insulin delivery and diabetes technology company, today announced the launch of Tandem Source, a diabetes management platform for insulin pump users and healthcare providers (HCPs).

– First Automated Insulin Delivery System in the World to Feature Dexcom’s Most Advanced CGM Technology – SAN DIEGO --(BUSINESS WIRE)--Dec. 6, 2023-- Tandem Diabetes Care, Inc. (NASDAQ: TNDM), a leading insulin delivery and diabetes technology company, today announced the launch of updated t:slim

SAN DIEGO --(BUSINESS WIRE)--Nov. 6, 2023-- Tandem Diabetes Care, Inc. (NASDAQ: TNDM), a leading insulin delivery and diabetes technology company, today announced that management will present a company update at the following investor conferences: Jefferies London Healthcare Conference on Tuesday,

SAN DIEGO --(BUSINESS WIRE)--Nov. 1, 2023-- Tandem Diabetes Care, Inc. (NASDAQ: TNDM), a leading insulin delivery and diabetes technology company, today announced the appointment of Mark Novara as Executive Vice President and Chief Commercial Officer, effective November 13, 2023 . Mr.

SAN DIEGO --(BUSINESS WIRE)--Nov. 1, 2023-- Tandem Diabetes Care, Inc. (NASDAQ: TNDM), a global insulin delivery and diabetes technology company, today reported its financial results for the quarter ended September 30, 2023 and updated its financial guidance for the year ending December 31, 2023 .

SAN DIEGO --(BUSINESS WIRE)--Oct. 10, 2023-- Tandem Diabetes Care, Inc. (NASDAQ: TNDM), a leading insulin delivery and diabetes technology company, plans to release its third quarter 2023 results after the financial markets close on Wednesday, November 1, 2023 .

SAN DIEGO --(BUSINESS WIRE)--Aug. 24, 2023-- Tandem Diabetes Care, Inc. (NASDAQ: TNDM), a leading insulin delivery and diabetes technology company, today announced that management will present a company update at the following investor conferences: 2023 Wells Fargo Healthcare Conference on

SAN DIEGO --(BUSINESS WIRE)--Aug. 3, 2023-- Tandem Diabetes Care, Inc. (NASDAQ: TNDM), a leading insulin delivery and diabetes technology company, today announced a limited time offer for its Tandem Choice technology access program. This program provides new and renewing, eligible t:slim X2 Insulin

SAN DIEGO --(BUSINESS WIRE)--Aug. 3, 2023-- Tandem Diabetes Care, Inc. (NASDAQ: TNDM), a global insulin delivery and diabetes technology company, today reported its financial results for the quarter ended June 30, 2023 and updated its financial guidance for the year ending December 31, 2023 .

SAN DIEGO --(BUSINESS WIRE)--Aug. 1, 2023-- Tandem Diabetes Care, Inc. (NASDAQ: TNDM), a leading insulin delivery and diabetes technology company, today announced that management will present a company update at the UBS MedTech, Tools and Genomics Summit 2023 on Wednesday, August 16, 2023 at 2:00pm

SAN DIEGO --(BUSINESS WIRE)--Jul. 11, 2023-- Tandem Diabetes Care, Inc. (NASDAQ: TNDM), a leading insulin delivery and diabetes technology company, today announced U.S. Food and Drug Administration (FDA) clearance for the Tandem Mobi insulin pump for people with diabetes age 6 and up, expanding the

SAN DIEGO --(BUSINESS WIRE)--Jul. 10, 2023-- Tandem Diabetes Care, Inc. (NASDAQ: TNDM), a leading insulin delivery and diabetes technology company, plans to release its second quarter 2023 results after the financial markets close on Thursday, August 3, 2023 .